NeoPharm
Near-Term Strategy PDF Print E-mail

NeoPharm’s near-term strategy focuses on optimizing its drug development activities, as follows:  

     ·  Progress several liposomal drug product candidates through Phase II completion   

     ·  Progress IL13-PE38 drug product candidate through Phase I completion 

     ·  Ensure regulatory compliance with all drug candidates 

     ·  Protect and enhance the value of NeoPharm’s intellectual property

The company also continues to identify new out-license and partnership opportunities where there might be a good fit with its current drug portfolio.

 

 

 

 

 

 
 


With a reorganization strategy originally announced in April 2007, NeoPharm has achieved significant cost-savings and put into place an optimal cost structure which enables the Company to focus primarily on the development of drug candidates.